BCR-ABL Directed Immunotherapy: A Virtual Reality?

References

• Chen W., Peace D. J., Rovira D. K., You S. G., Cheever M. A. T cell immunity to the joining region of p210BCR-ABL.protein. Proceedings National Academy of Sciences 1992; 89: 1468–1472
   PubMed Web of Science ®Google Scholar
• Ten Bosch G. J. A., Toomvliet A. C., Friede T., Melief C. J. M., Leeksma O. C. Recognition of etides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 1995; 9: 1344–1348
   PubMed Web of Science ®Google Scholar
• Yotnda P., Firat H., Garcia-Pons F., Garcia Z., Gounv G., Vemant J. P., Lemonnier F. A., Leblond V., Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. Journal of Clinical Investigation 1998; 101: 2290–2296
   PubMed Web of Science ®Google Scholar
• Kessler J. H., et al, manuscript in preparation
   Google Scholar
• Bocchia M., Wentworth P. A., Southwood S., Sidney J., McGraw K., Scheinberg D. A., Sette A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. BLOOD 1995; 85: 2680–2684
   PubMed Web of Science ®Google Scholar
• Greco G., Fruci D., Accapezzato D., Bamaba V., Nisini R., Alimena G., Montefusco E., Vigneti E., Butler R., Tanigaki N., Tosi R. Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996; 10: 693–699
   PubMed Web of Science ®Google Scholar
• Nieda M., Nicol A., Kikuchi A., Kashiwase K., Taylor K., Suzuki K., Tadokoro K., Juji T. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemia cells from patients with chronic myeloid leukemia. BLOOD 1998; 91: 977–983
   PubMed Web of Science ®Google Scholar
• Buzyn A., Ostankovitch M., Kbib A., Kemula M., Connan F., Varet B., Guillet J. G., Choppin J. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. European Journal of Immunology 1997; 27: 2066–2072
   PubMed Web of Science ®Google Scholar
• Mannering S. I., McKenzie J. L., Fearnley D. B., Hart D. N. J. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen- presenting cells exposed to b3a2 containing cell lysates. BLOOD 1997; 90: 290–297
   PubMed Web of Science ®Google Scholar
• Ten Bosch G. J. A., et al, unpublished observation
   Google Scholar
• Pawelec G., Max H., Halder Th., Bruserud Ø., Merl A., Da Silva P., Kalbacher H. BC/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. BLOOD 1996; 88: 2118–212
   PubMed Web of Science ®Google Scholar
• Ten Bosch G. J. A., Joosten A. M., Kessler J. H., Melief C. J. M., Leeksma O. C. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunisation with a BCR-ABL breakpoint peptide. BLOOD 1996; 88: 3522–3527
   PubMed Web of Science ®Google Scholar
• Yasukawa M., Ohminami H., Kaneko S., Yakushijin Y., Nishimura Y., Inokuchi K., Miyakuni T., Nakao S., Kishi K., Kubonishi I., Dan K., Fujita S. CD4+ Cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. BLOOD 1998; 92: 3355–3361
   PubMed Web of Science ®Google Scholar
• Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S. Y., Sette A., Scheinberg D. A. Specific human cellular immunity to bcr-abl oncogene-derived peptides. BLOOD 1996; 87: 3587–3592
   PubMed Web of Science ®Google Scholar
• Ten Bosch G. J. A., Kessler J. H., Joosten A. M., Van Bergen J., Bres-Vloemans A. A., Geluk A., Godthelp B., Melief C. J. M., Leeksma O. C. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an lib2a2 construct. BLOOD 1999; 94: 1038–1045
   PubMed Web of Science ®Google Scholar
• Papadopoulos K. P., Suciu-Foca N., Hesdorffer C. S., Tugulea S., Maffei A., Harris P. E. Naturally processed tis-sue-and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. BLOOD 1997; 90: 4938–4946
   PubMed Web of Science ®Google Scholar
• Breitschopf K., Bengal E., Ziv T., Admon A., Ciechano-ver A. A novel site for ubiquitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. The Embo Journal 1998; 17: 5964–5973
   PubMed Web of Science ®Google Scholar
• Baumeister W., Walz I., Zühl F., Seemüller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998; 92: 367–380
   PubMed Web of Science ®Google Scholar
• Rock K. L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761–771
   PubMed Web of Science ®Google Scholar
• Craiu A., Gaczynska M., Akopian T., Gramm C. F., Fenteany G., Goldberg A. L., Rock K. L. Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. The Journal of Biological Chemistry 1997; 272: 13437–13445
   PubMed Web of Science ®Google Scholar
• Saglio G., Guerrasio A., Rosso C., Zaccaria A., Tassinari A., Serra A., Rege-Cambrin G., Mazza U., Gavosto F. New type of BCR/ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia. BLOOD 1990; 76: 1819–1824
   PubMed Web of Science ®Google Scholar
• Wada H., Mizutani S., Nishimura J., Usuki J., Kohsaki M., Komai M., Kaneko H., Sakamoto S., Delia D., Kanamura A., Kakishita E. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Research 1995; 55: 3192–3196
   PubMed Web of Science ®Google Scholar
• Heisterkamp N., Stam K., Groffen J., De Klein A., Gros-veld G. Structural organisation of the bcr gene and its role in the Ph' translocation. Nature 1985; 315: 758–761
   PubMed Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550–554
   PubMed Web of Science ®Google Scholar
• Grosveld G., Verwoerd T., Van Agthove T., De Klein A., Ramachandran K. L., Stam K., Groffen J. The chronic myelocytic leukemia cell line K562 contains a breakpoint in bcr and produces a chimeric bcr-c-abl transcript. Molecular Cell Biology 1986; 6: 607–616
   PubMed Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., Roe B. A., Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the BCR-ABL fused gene. Cell 1986; 47: 277–284
   PubMed Web of Science ®Google Scholar
• How G. F., Lim L. C., Kulkarni S., Tan L. T., Tan P., Cross N. C. P. Two patients with novel BCR/ABL fusion transcripts (e8a2 and e13a2) resulting from translocation breakpoints within BCR exons. British Journal of Haematology 1999; 105: 434–436
   PubMed Web of Science ®Google Scholar
• Inukai T., Sugita K., Suzuki T., Ijima K., Goi K., Tezuka T., Kojika S., Hatakeyama K., Kagami K., Mori T., Okazaki T., Mizutani S., Nakazawa S. A novel 203kD aberrant BCR-ABL product in a girl with Philadelphia chromosome positive acute lymphoblastic leukaemia. British Journal of Haematology 1993; 85: 823–825
   PubMed Web of Science ®Google Scholar
• Iwata S., Mizutani S., Nakazawa S., Yata J. I. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia 1994; 8: 1696–1702
   PubMed Web of Science ®Google Scholar
• Van der Plas D. C., Soekarman D., van Gent A. M., Grosveld G., Hagemeijer A. bcr-abl mRNA lacking abl exon A2 detected by polymerase chain reaction in a chronic myelogenous leukemia. Leukemia 1991; 5: 457–461
   PubMed Web of Science ®Google Scholar
• Inokuchi K., Futaki M., Hanawa H., Tanosaki S., Jamaguchi H., Iwakiri R., Nomura T., Dan K. Heterogeneous expression of BCR-ABL fusion mRNA in a patient with Philadelphia-chromosome-positive acute lymphoblastic leukaemia. British Journal of Haematology 1997; 97: 837–840
   PubMed Web of Science ®Google Scholar
• Hochhaus A., Reiter A., Reiter A., Skladny H., Melo J. V., Sick C., Berger U., Guo J. Q., Arlinghaus R. B., Hehlmann R., Goldman J. M., Cross N. C. P. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. BLOOD 1996; 88: 2236–2240
   PubMed Web of Science ®Google Scholar
• Martinelli G., Terragna C., Amabile M., Montefusco V., Tes-toni N., Ottaviani E., de Vivo A., Mianulli A., Saglio G., Tura S. Translin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimaeric BCR-ABL transcript (eS-INT-a2). BLOOD 1998; 92: 93a
   PubMed Web of Science ®Google Scholar
• Okamoto K., Karasawa M., Sakai H., Ogura H., Morita K., Naruse T. A novel acute lymphoid leukaemia type BCR/ABL transcript in chronic myelogenous leukaemia. British Journal of Haematology, 96: 611–613
   PubMed Web of Science ®Google Scholar
• Byrne J. L., Carter G. I., Davies J. M., Haynes A. P., Russell N. H., Cross N. C. P. A novel BCR-ABL fusion gene (e2–1a) in a patient with Philadelphia-positive chronic myelogenous leukemia and an aggressive clinical course. British Journal of Haematology 1998; 103: 791–794
   PubMed Web of Science ®Google Scholar
• Hermans A., Heisterkamp N., von Lindem M., van Baal S., Meijer D., van der Plas D., Wiedemann L. M., Groffen J., Bootsma D., Grosveld G. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33–39
   PubMed Web of Science ®Google Scholar
• Melo J. V., Myint H., Galton D. A., Goldman J. M. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?. Leukemia 1994; 8: 208–211
   PubMed Web of Science ®Google Scholar
• Saglio G., Pane F., Gottardi E., Frigeri E., Buonaiuto M. R., Guerrasio A., De Micheli D., Parziale A., Fornaci M. N., Martinelli G., Salvatore F. Consistent amounts of acute leukemia-associated p190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. BLOOD 1996; 87: 1075–1080
   PubMed Web of Science ®Google Scholar
• van Rhee F., Hochhaus A., Lin F., Melo J. V., Goldman J. M., Cross N. C. P. P190BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemia. BLOOD 1996; 87: 5213–5221
   PubMed Web of Science ®Google Scholar
• van Soekarman D., Denderen J., Hoefsloot L., Moret M., Meeuwsen T., van Baal J., Hagemeijer A., Grosveld G. Leukemia 1990; 4: 397–403
   PubMed Web of Science ®Google Scholar
• Mingari M. C., Moretta A., Moretta L. Regulation of KIR expression in human T lymphocytes. A safety mechanism which may impair protective T cell responses. Immunology Today 1998; 19: 153–157
   PubMedGoogle Scholar
• Sanchez M., Alfani M., Visconti G., Passarelli A. M., Migliacco A. R., Migliacco G. Thymus-independent T-cell differentiation in vitro. British Journal of Haematology 1998; 103: 1198–1205
   PubMed Web of Science ®Google Scholar
• Pawelec G., Muller R., Rehbein A., Hahnel K., Ziegler B. L. Extrathymic T cell differentiation in vitro from CD34+ stem cells. Journal of Leukocyte Biology 1998; 64: 733–739
   PubMed Web of Science ®Google Scholar
• Hemmer B., Vergeli M., Gran B., Ling N., Conlon P., Pinilla C., Houghten R., McFarland H. F., Martin R. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. Journal of Immunology 1998; 160: 3631–363
   PubMed Web of Science ®Google Scholar
• Apostopoulos V., Lofthouse S. A., Popovski V., Chelvanayagam G., Sandrin M., McKenzie I. F. C. Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nature Biorechnology 1998; 16: 276–280
   PubMed Web of Science ®Google Scholar
• Ten Bosch G. J. A., Joosten A. M., Melief C. J. M., Leeksma O. C. Cross reactivity of BCR-ABL peptide specific T cells with EBV transformed B cells. BLOOD 1994; 84: 432a
   Web of Science ®Google Scholar
• Biernaux C., Loos M., Sels A., Huez G., Stryckmans. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. BLOOD 1995; 86: 3118–3122
   PubMed Web of Science ®Google Scholar
• Bose S., Deininger M., Gora-vbor M., Goldman J., Melo J. V. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. BLOOD 1998; 92: 3362–3367
   PubMed Web of Science ®Google Scholar
• Oettel K. R., Wesly O. H., Albertini M. R., Hank J. A., Iliopolis O., Sosman J., Voelkerding K., Wu S. -Q., Clark S. S., Son-dell P. M. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient. BLOOD. 1994; 83: 3390–3402
   PubMed Web of Science ®Google Scholar
• Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S., Zimmerman M., Lydon N. B. Effects of a selective inhibitor of the Abelson tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• Le Coutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F., Gambacorti-Passerini C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. Journal of the National Cancer Institute 1999; 91: 163–168
   PubMed Web of Science ®Google Scholar
• Albert M. L., Sauter B., Bardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class-I-restricted CTLs. Nature 1998; 392: 86–89
   PubMed Web of Science ®Google Scholar
• Boussiotis V. K., Freeman G. J., Berezovskaya A., Barber D. L., Nadler L. M. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rapl. SCIENCE 1997; 278: 124–127
   PubMed Web of Science ®Google Scholar
• Ten Bosch G. J. A., Kessler J. H., Blom J., Joosten A. M., Gambacorti-Passerini C., Melief C. J. M., Leeksma O. C. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. British Journal of Haemarology 1998; 103: 1109–1115
   PubMed Web of Science ®Google Scholar
• Watai K., Tojo T., Nagamura-Inoue T., Tsujimura H., Nagamura F., Tani K., Asano S. A new melanoma antigen, PRAME, is identified as a BCR-ABL-inducible gene in TF-1 cells. BLOOD 1997; 90: 197a
   Google Scholar
• Chen C., Umezu K., Kolodner R. Chromosomal rearrangements occur in s. cerevisiae rfal mutator mutants due to mutagenic lesions processed by double-strand-break repair. Molecular Cell 1998; 2: 9–22
   PubMed Web of Science ®Google Scholar